Akoya Biosciences, Inc.’s AKYA share price has dipped by 7.20%, which has investors questioning if this is right time to buy.

Piper Sandler analyst David Westenberg lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.65 from $2.40 and keeps a Neutral ...

Piper Sandler analyst David Westenberg maintained a Hold rating on Akoya Biosciences (AKYA – Research Report) today and set a price target of ...

Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today announced that it has filed ...

Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. The company had revenue of $21.34 million for the quarter, compared to the consensus estimate of ...

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences ...

In other recent news, Akoya Biosciences reported its fourth-quarter results for 2024, which aligned with both Canaccord Genuity’s and FactSet’s consensus estimates. The company’s revenue ...

Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challengesinitiative The unprecedented scale ...

Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences ("Akoya") (NASDAQ: ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA),announced Wednesday that its PhenoCycler-Fusion system has been chosen as the foundational spatial proteomics technology for a groundbreaking cancer ...

SAMBAI, a team funded through the Cancer Grand Challenges initiative, reported that Akoya Biosciences’ PhenoCycler ®-Fusion system will be the foundational spatial proteomics technology used to ...